Cargando…
Inhibition of Ebola Virus by a Molecularly Engineered Banana Lectin
Ebolaviruses cause an often rapidly fatal syndrome known as Ebola virus disease (EVD), with average case fatality rates of ~50%. There is no licensed vaccine or treatment for EVD, underscoring the urgent need to develop new anti-ebolavirus agents, especially in the face of an ongoing outbreak in the...
Autores principales: | Covés-Datson, Evelyn M., Dyall, Julie, DeWald, Lisa Evans, King, Steven R., Dube, Derek, Legendre, Maureen, Nelson, Elizabeth, Drews, Kelly C., Gross, Robin, Gerhardt, Dawn M., Torzewski, Lisa, Postnikova, Elena, Liang, Janie Y., Ban, Bhupal, Shetty, Jagathpala, Hensley, Lisa E., Jahrling, Peter B., Olinger, Gene G., White, Judith M., Markovitz, David M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687191/ https://www.ncbi.nlm.nih.gov/pubmed/31356611 http://dx.doi.org/10.1371/journal.pntd.0007595 |
Ejemplares similares
-
Lack of Effect of Lamivudine on Ebola Virus Replication
por: Hensley, Lisa E., et al.
Publicado: (2015) -
A molecularly engineered antiviral banana lectin inhibits fusion and is efficacious against influenza virus infection in vivo
por: Covés-Datson, Evelyn M., et al.
Publicado: (2020) -
In Vivo Activity of Amodiaquine against Ebola Virus Infection
por: DeWald, Lisa Evans, et al.
Publicado: (2019) -
Targeted disruption of pi–pi stacking in Malaysian banana lectin reduces mitogenicity while preserving antiviral activity
por: Covés-Datson, Evelyn M., et al.
Publicado: (2021) -
Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo
por: Finch, Courtney L., et al.
Publicado: (2021)